Abstract

To find a new way for gene therapy against tumors with weak immunogenicity, the effect of mB7-1 costimulation alone, or combined with IL-6, in inducing antitumor immunity in vitro was investigated. It was found that mB7-1 cD-NA transfected B16 cells (B16-mB7-1) induced the expansion of effector lymphocytes and the generation of specific lytic activity more effectively than wild type B16 melanoma cells (B16-wt) or mock-transfected B16 cells (B16-neo) did. (P < 0.01), IL-6 could effectively stimulate lymphocytes proliferation, but failed to enhance its cytotoxicity, while the combination of mB7-1 and IL-6 increased both lymphocyte proliferative response and T-cell-mediated cytotoxicity more significantly than B7-1 or IL-6 did alone (P < 0.01). It was inferred that the costimulatory molecule B7-1 is required for the activation and proliferation of T lymphocytes; the expression of mB7-1 in tumor cells could increase their immunogenicity and induce effective antitumor immune response, and the combination of B7-1 and IL-6 could induce more effective antitumor immunity, indicating that cooperation of IL-6 and mB7-1 plays a role in T lymphocyte activation.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.